• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Postoperative simple biochemical markers for prediction of bone metastases in Egyptian breast cancer patients.用于预测埃及乳腺癌患者骨转移的术后简单生化标志物
Ecancermedicalscience. 2013 Apr 15;7:305. doi: 10.3332/ecancer.2013.305. Print 2013.
2
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
3
Evaluation of bone metabolic markers in breast cancer with bone metastasis.乳腺癌骨转移患者骨代谢标志物的评估
Breast Cancer. 2001;8(2):131-7. doi: 10.1007/BF02967492.
4
Detection of Bone Metastases in Breast Cancer (BC) Patients by Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b), a Bone Resorption Marker and Serum Alkaline Phosphatase (ALP), a Bone Formation Marker, in Lieu of Whole Body Skeletal Scintigraphy with Technetium99m MDP.采用骨吸收标志物血清抗酒石酸酸性磷酸酶5b(TRACP 5b)和骨形成标志物血清碱性磷酸酶(ALP)检测乳腺癌(BC)患者的骨转移,以替代使用锝99m亚甲基二膦酸盐进行的全身骨骼闪烁扫描。
Indian J Clin Biochem. 2015 Jan;30(1):66-71. doi: 10.1007/s12291-013-0399-8. Epub 2013 Nov 20.
5
Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation.12种血管生成、肿瘤侵袭和骨转换血清生化标志物与乳腺癌骨转移的关联:一项横断面和纵向评估
Br J Cancer. 2006 Aug 21;95(4):506-14. doi: 10.1038/sj.bjc.6603285. Epub 2006 Aug 1.
6
A summary of two clinical studies on tumor cell dissemination in primary and metastatic breast cancer: methods, prognostic significance and implication for alternative treatment protocols (Review).两项关于原发性和转移性乳腺癌中肿瘤细胞播散的临床研究综述:方法、预后意义及对替代治疗方案的启示(综述)
Int J Oncol. 2002 May;20(5):1027-34. doi: 10.3892/ijo.20.5.1027.
7
Isoenzymes of alkaline and acid phosphatases as bones metastasis marker in breast cancer patients.碱性磷酸酶和酸性磷酸酶同工酶作为乳腺癌患者骨转移标志物的研究
Anticancer Res. 1989 Jul-Aug;9(4):1105-9.
8
[Evaluation of two serum isoenzyme phosphatases as bone metastasis markers].[两种血清同工酶磷酸酶作为骨转移标志物的评估]
Bull Cancer. 1990;77(12):1211-21.
9
Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy.用于检测前列腺癌患者骨转移的生化标志物:诊断效能及激素治疗的影响
J Bone Miner Metab. 2001;19(1):45-51. doi: 10.1007/s007740170059.
10
Application of Bone Turnover Markers PICP and β-CTx in the Diagnosis and Treatment of Breast Cancer with Bone Metastases.骨转换标志物I型前胶原羧基端前肽(PICP)和β-交联羧基端肽(β-CTx)在乳腺癌骨转移诊断与治疗中的应用
Clin Lab. 2018 Jan 1;64(1):11-16. doi: 10.7754/Clin.Lab.2017.161021.

引用本文的文献

1
Diagnostic value of alkaline phosphatase and bone-specific alkaline phosphatase for metastases in breast cancer: a systematic review and meta-analysis.碱性磷酸酶和骨碱性磷酸酶对乳腺癌转移的诊断价值:系统评价和荟萃分析。
Breast Cancer Res Treat. 2023 Nov;202(2):233-244. doi: 10.1007/s10549-023-07066-z. Epub 2023 Jul 31.
2
Preoperative alkaline phosphatase-to-platelet count ratio as a prognostic factor for hepatocellular carcinoma with microvascular invasion.术前碱性磷酸酶与血小板计数比值作为微血管侵犯型肝细胞癌的预后因素
Cancer Med. 2023 Sep;12(17):17545-17558. doi: 10.1002/cam4.6368. Epub 2023 Jul 26.
3
Association between Bone Mineral Density and Bone Turnover Markers in Breast Cancer Patients and Bone-Only Metastasis.乳腺癌患者的骨密度与骨转换标志物的相关性与仅有骨转移。
Medicina (Kaunas). 2021 Aug 26;57(9):880. doi: 10.3390/medicina57090880.
4
Elevated preoperative serum cancer antigen 15.3 levels are associated with reduced disease-free survival: a single-institution experience.术前血清癌抗原 15.3 水平升高与无病生存时间降低相关:单中心经验。
Breast Cancer (Dove Med Press). 2013 Jul 26;5:53-9. doi: 10.2147/BCTT.S48568. eCollection 2013.

本文引用的文献

1
Breast cancer: surgery at the South egypt cancer institute.乳腺癌:在埃及南部癌症研究所进行的手术。
Cancers (Basel). 2010 Sep 30;2(4):1771-8. doi: 10.3390/cancers2041771.
2
Value of TRAcP 5b as a diagnostic marker for detection of bone metastases in patients with breast cancer.抗酒石酸酸性磷酸酶5b(TRAcP 5b)作为乳腺癌患者骨转移检测诊断标志物的价值。
Eur J Gynaecol Oncol. 2011;32(6):615-8.
3
Leukocyte-derived microparticles in vascular homeostasis.白细胞衍生的微粒在血管稳态中的作用。
Circ Res. 2012 Jan 20;110(2):356-69. doi: 10.1161/CIRCRESAHA.110.233403.
4
Genome-wide analysis discloses reversal of the hypoxia-induced changes of gene expression in colon cancer cells by zinc supplementation.全基因组分析揭示了锌补充剂可逆转缺氧诱导的结肠癌细胞基因表达变化。
Oncotarget. 2011 Dec;2(12):1191-202. doi: 10.18632/oncotarget.395.
5
Metadherin mediates lipopolysaccharide-induced migration and invasion of breast cancer cells.金属硫蛋白诱导脂多糖诱导的乳腺癌细胞迁移和侵袭。
PLoS One. 2011;6(12):e29363. doi: 10.1371/journal.pone.0029363. Epub 2011 Dec 16.
6
Tumour macrophages as potential targets of bisphosphonates.肿瘤相关巨噬细胞作为双膦酸盐类药物的潜在作用靶点。
J Transl Med. 2011 Oct 17;9:177. doi: 10.1186/1479-5876-9-177.
7
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma.初诊时外周血淋巴细胞/单核细胞比值与经典型霍奇金淋巴瘤患者的生存。
Haematologica. 2012 Feb;97(2):262-9. doi: 10.3324/haematol.2011.050138. Epub 2011 Oct 11.
8
Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.接受“节拍式”唑来膦酸治疗的乳腺癌伴骨转移患者的临床和生化因素的预后和预测价值。
BMC Cancer. 2011 Sep 22;11:403. doi: 10.1186/1471-2407-11-403.
9
Building multi-marker algorithms for disease prediction-the role of correlations among markers.构建用于疾病预测的多标记算法——标记间相关性的作用。
Biomark Insights. 2011;6:83-93. doi: 10.4137/BMI.S7513. Epub 2011 Aug 14.
10
Interaction of tumor cells with the microenvironment.肿瘤细胞与微环境的相互作用。
Cell Commun Signal. 2011 Sep 13;9:18. doi: 10.1186/1478-811X-9-18.

用于预测埃及乳腺癌患者骨转移的术后简单生化标志物

Postoperative simple biochemical markers for prediction of bone metastases in Egyptian breast cancer patients.

作者信息

Morcos Nadia Ys, Zakhary Nadia I, Said Mahmoud M, Tadros May Mm

机构信息

Biochemistry Department, Faculty of Science, Ain Shams University, Egypt.

出版信息

Ecancermedicalscience. 2013 Apr 15;7:305. doi: 10.3332/ecancer.2013.305. Print 2013.

DOI:10.3332/ecancer.2013.305
PMID:23653670
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3640610/
Abstract

OBJECTIVE

The present study was undertaken to identify patient populations at high risk for bone metastases (BM) at any time after diagnosis of operable breast cancer.

SUBJECTS AND METHODS

A total number of 59 cases with breast cancer after mastectomy was subdivided into two main groups that included 30 patients with radiologically confirmed BM and 29 patients with no bone metastasis (NBM). Patients with NBM were formerly observed for a one-year follow-up interval to monitor the development of bone metastasis (new BM). Parameters included a full blood picture, tumour markers (carcinoembryonic antigen and CA 15.3) and some biochemical markers (vascular endothelial growth factor and zinc levels, as well as tartrate-resistant acid phosphatase and alkaline phosphatase activities).

RESULTS

A significant elevation was recorded in carcinoembryonic antigen level and alkaline phosphatase activity, as well as inflammation and vascularisation markers at the time of primary diagnosis in patients with BM, compared with those without BM. CA 15.3 was significantly higher in the new BM group as compared with the other two groups (patients free of bone metastasis [free BM] and BM). According to the likelihood ratio, a panel of single, calculated as well as combined markers was proposed to predict BM within one year in breast cancer patients.

CONCLUSION

Vascularisation and inflammation markers, as well as CA 15.3 are predictive of bone recurrence within one year in breast carcinoma patients. We suggest that in cancer validation studies it is imperative to search for markers that link to the premetastatic process and to determine what type of mechanism is active in each stage.

摘要

目的

本研究旨在确定可手术乳腺癌诊断后任何时间发生骨转移(BM)的高危患者群体。

对象与方法

59例乳腺癌乳房切除术后患者被分为两个主要组,其中30例经放射学证实有骨转移,29例无骨转移(NBM)。对NBM患者进行为期一年的随访,以监测骨转移(新的BM)的发生情况。参数包括全血细胞计数、肿瘤标志物(癌胚抗原和CA 15.3)以及一些生化标志物(血管内皮生长因子和锌水平,以及抗酒石酸酸性磷酸酶和碱性磷酸酶活性)。

结果

与无BM的患者相比,BM患者在初次诊断时癌胚抗原水平、碱性磷酸酶活性以及炎症和血管生成标志物均显著升高。新的BM组的CA 15.3显著高于其他两组(无骨转移[无BM]患者和BM患者)。根据似然比,提出了一组单一、计算得出以及组合的标志物,用于预测乳腺癌患者一年内的BM情况。

结论

血管生成和炎症标志物以及CA 15.3可预测乳腺癌患者一年内的骨复发情况。我们建议在癌症验证研究中,必须寻找与转移前过程相关的标志物,并确定每个阶段活跃的机制类型。